Journal of advanced research · 2025
MeCP2 dysregulation inhibits mitophagy and impairs neural development in cortical organoids.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Jing, Liu Yuchun, Jing Xintao, Peng Hang, Li Fang, Cao Li, Li Wen, Li Rufeng, Zhang Jinyuan, Wang Xiaofei, Lian Jiangfang, Tong Dongdong, Huang Chen
Аннотация
INTRODUCTION: Methylated CpG-binding protein 2 (MeCP2) plays a critical role in the normal development and function of the nervous system. Mutations in MeCP2 have been linked to neurodevelopmental disorders, potentially because of mitochondrial dysfunction and impaired mitophagy. However, the underlying mechanisms remain poorly understood. Investigating the role of MeCP2 in the regulation of mitophagy is essential for elucidating the pathogenesis of these disorders.
OBJECTIVES: The aim of the present study was to explore the molecular mechanisms by which MeCP2 regulates mitophagy and determine how its dysfunction contributes to neurodevelopmental abnormalities using cortical organoids (COs) derived from MeCP2 mutant induced pluripotent stem cells (iPSCs).
METHODS: CRISPR-Cas9 technology was used to generate MeCP2 mutant iPSCs, which were then differentiated into cortical organoids. Growth, proliferation, and differentiation of neural stem cells in these organoids were analysed. Single-cell RNA sequencing was performed to assess the changes in gene expression, focusing on mitophagy-related genes. MeCP2 occupancy at the BNIP3L transcription start site (TSS) was also examined.
RESULTS: MeCP2 mutant COs exhibited growth inhibition, abnormal proliferation, and disrupted neural stem cell differentiation. Single-cell RNA sequencing revealed a significant downregulation of BNIP3L, a key mitophagy receptor. MeCP2 was found to occupy the BNIP3L TSS, leading to suppressed BNIP3L expression and impaired mitophagy in COs.
CONCLUSION: The obtained findings demonstrate that MeCP2 regulates mitophagy by modulating BNIP3L expression, and its dysfunction leads to mitochondrial accumulation and neurodevelopmental abnormalities. The present study highlights the critical role of MeCP2 in maintaining mitochondrial homeostasis and provides insights into the molecular mechanisms underlying MeCP2-related neurodevelopmental disorders.
OBJECTIVES: The aim of the present study was to explore the molecular mechanisms by which MeCP2 regulates mitophagy and determine how its dysfunction contributes to neurodevelopmental abnormalities using cortical organoids (COs) derived from MeCP2 mutant induced pluripotent stem cells (iPSCs).
METHODS: CRISPR-Cas9 technology was used to generate MeCP2 mutant iPSCs, which were then differentiated into cortical organoids. Growth, proliferation, and differentiation of neural stem cells in these organoids were analysed. Single-cell RNA sequencing was performed to assess the changes in gene expression, focusing on mitophagy-related genes. MeCP2 occupancy at the BNIP3L transcription start site (TSS) was also examined.
RESULTS: MeCP2 mutant COs exhibited growth inhibition, abnormal proliferation, and disrupted neural stem cell differentiation. Single-cell RNA sequencing revealed a significant downregulation of BNIP3L, a key mitophagy receptor. MeCP2 was found to occupy the BNIP3L TSS, leading to suppressed BNIP3L expression and impaired mitophagy in COs.
CONCLUSION: The obtained findings demonstrate that MeCP2 regulates mitophagy by modulating BNIP3L expression, and its dysfunction leads to mitochondrial accumulation and neurodevelopmental abnormalities. The present study highlights the critical role of MeCP2 in maintaining mitochondrial homeostasis and provides insights into the molecular mechanisms underlying MeCP2-related neurodevelopmental disorders.